Royalty Pharma's recent performance and growth prospects have garnered increased attention, highlighted by multiple stock upgrades including prominent firms like UBS and Morgan Stanley. The company achieved a new 1-year high and demonstrated a considerable growth profile. Investments have altered in the landscape; some firms such as Ruffer LLP and Mitsubishi UFJ Trust & Banking Corp decreasing holdings, while others like Oxbow Advisors LLC, Hosking Partners LLP, and Robeco Institutional Asset Management B.V. increased their position. Insider trading painted a mixed picture, with several executives, including EVP Coyne and Urist, selling shares, while the company upped its dividend and provided bullish guidance. This was reinforced by a strong 1-year return and high Q3 earnings. Amid these developments, Royalty Pharma secured a $2B senior notes offering and inked major partnership deals, including a $275Mln deal with Denali, and purchased new oncology royalty. However, investors and analysts remain cautious, scrutinizing its valuation, recent outperformance, insider trading, and revenue miss in Q2.
Royalty Pharma Stocks News Analytics from Sun, 11 May 2025 07:00:00 GMT to Sat, 31 Jan 2026 18:57:38 GMT - Rating 7 - Innovation -2 - Information 8 - Rumor -5
